Innovation in Drug Discovery for Pharma and Biotech

​Join us for an event tailored for pharmaceutical and biotech executives. This half-day session will explore how to revolutionize drug development, reduce time-to-market, improve operational efficiency, and enhance global collaboration.

Held at The Oxford Science Park, this exclusive event offers practical insights to drive research productivity and regulatory excellence. The agenda includes discussions on seamless integration and data-driven decision-making, providing executives with the tools to navigate the evolving landscape of life sciences and gain a competitive edge in R&D.

Agenda:
8.30 AM - 9.30 AM - Registration and Breakfast
9.30 AM - 10.00 AM - Opening Remarks
10.00 AM - 11.00 AM - Panel Discussion
11.00 AM - 11.15 AM - Closing Remarks
11.15 AM - Noon - Mix and Mingle
Noon - Meeting Ends

​
Speakers:

​Colin Weller
VP Product - Data and Innovative Data Products
Medable, inc.

Medable provides an end-to-end, global cloud platform with a flexible suite of tools that allows sponsors, patients, providers & CRO's to work together as a team in clinical trials, enabling more efficient clinical research, more effective healthcare delivery, and more accurate precision and predictive medicine

Davy Yeung
Managing Director & VP of Operations
Tailored Clinical Research Solutions (TCRS)

TCRS provides a full range of clinical development services to pharma companies, biotechs, and university academics. Working in close partnership with hospital sites, TCRS delivers integrated, cost-managed trial solutions that put patients first

Mike Rea
CEO
IDEA Pharma

IDEA Pharm is the industry leader in early-phase positioning and path-to-market strategy. The Pharmaceutical Innovation Index is the industry-standard ranking of innovation.

IDEA has positioned 8 of the 15 biggest drug launches of the past 3 years, and 25% of the 50 fastest-growing new medicines in the last 5 years - including Opdivo, the most successful oncology launch ever, and Ocrevus, which Roche claims as their best-ever launch.

Hazel Jones
CEO
Enhanc3d Genomics

ENHANC3D GENOMICS are creating new applications to improve human healthcare. The company has developed technology that profiles 3D genome folding at high resolution for all genes and their enhancers simultaneously and thus links gene enhancers and non-coding genetic variants to their target genes to unlock their potential for therapeutic discovery.

Enhanc3D Genomics is a spinout company from Babraham Institute (Cambridge, UK), founded by academic scientists who are leaders in the fields of regulatory genomics and chromosomal architecture.